{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:14:00Z","timestamp":1787066040768,"version":"build-2736575974"},"reference-count":82,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2020,2,18]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Obesity represents the second preventable mortality cause worldwide, and is very often associated with type 2 Diabetes Mellitus (T2DM). The first line treatment is lifestyle modification to weight-loss, but for those who fail to achieve the goal or have difficulty in maintaining achieved results, pharmacological treatment is needed. Few drugs are available today, because of their side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>We aim to review actual pharmacological management of obese patients, highlighting differences between Food and Drug Administration - and European Medicine Agency-approved molecules, and pointing out self-medications readily obtainable and widely distributed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Papers on obesity, weight loss, pharmacotherapy, self- medication and diet-aid products were selected using Medline. Research articles, systematic reviews, clinical trials and meta-analyses were screened.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe. Phentermine\/topiramate and naltrexone\/bupropion combinations are now available, even though the former is still under investigation from EMA. Orlistat, with peripheral mechanisms, represents the only drug approved for weight reduction in adolescents. Liraglutide has been approved at higher dose for obesity. Anti-obesity drugs, readily obtainable from the internet, include crude-drug products and supplements for which there is often a lack of compliance to national regulatory standards.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Mechanisms of weight loss drugs include the reduction of energy intake or the increase in energy expenditure and sense of satiety as well as the decrease of hunger or the reduction in calories absorption. Few drugs are approved, and differences exist between USA and Europe. Moreover, herbal medicines and supplements often sold on the internet and widely used by obese patients, present a risk of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0929867326666190124121725","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T05:15:55Z","timestamp":1548393355000},"page":"174-186","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Obesity Therapy: How and Why?"],"prefix":"10.2174","volume":"27","author":[{"given":"Sara","family":"Paccosi","sequence":"first","affiliation":[{"name":"Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Cresci","sequence":"additional","affiliation":[{"name":"Diabetology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pala","sequence":"additional","affiliation":[{"name":"Diabetology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Maria","family":"Rotella","sequence":"additional","affiliation":[{"name":"Diabetology, Careggi University Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Parenti","sequence":"additional","affiliation":[{"name":"Department of Health Sciences, Clinical Pharmacology and Oncology Section, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-24532-4","author":"Massimo C.","year":"2016","unstructured":"Massimo C.; Eating Disorders and Obesity in: Clinical Management of Overweight and Obesity Recommendations of the Italian Society of Obesity (SIO) 2016,103-123","journal-title":"Eating Disorders and Obesity in: Clinical Management of Overweight and Obesity Recommendations of the Italian Society of Obesity (SIO)"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/oby.20394","volume":"21","author":"Bray G.A.","year":"2013","unstructured":"Bray G.A.; Why do we need drugs to treat the patient with obesity? Obesity (Silver Spring) 2013,21(5),893-899","journal-title":"Obesity (Silver Spring)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11892-017-0859-2","volume":"17","author":"Gadde K.M.","year":"2017","unstructured":"Gadde K.M.; Pritham Raj Y.; Pharmacotherapy of obesity: clinical trials to clinical practice. Curr Diab Rep 2017,17(5),34","journal-title":"Curr Diab Rep"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0092-8674(03)01081-X","volume":"116","author":"Flier J.S.","year":"2004","unstructured":"Flier J.S.; Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004,116(2),337-350","journal-title":"Cell"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.3389\/fphys.2014.00480","volume":"5","author":"Kim J.D.","year":"2014","unstructured":"Kim J.D.; Leyva S.; Diano S.; Hormonal regulation of the hypothalamic melanocortin system. Front Physiol 2014,5,480","journal-title":"Front Physiol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3389\/fnsys.2015.00142","volume":"9","author":"Gao X.B.","year":"2015","unstructured":"Gao X.B.; Hermes G.; Neural plasticity in hypocretin neurons: the basis of hypocretinergic regulation of physiological and behavioral functions in animals. Front Syst Neurosci 2015,9,142","journal-title":"Front Syst Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coph.2017.07.005","volume":"37","author":"Norton M.","year":"2017","unstructured":"Norton M.; Murphy K.G.; Targeting gastrointestinal nutrient sensing mechanisms to treat obesity. Curr Opin Pharmacol 2017,37,16-23","journal-title":"Curr Opin Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.coph.2017.09.002","volume":"37","author":"Heisler L.K.","year":"2017","unstructured":"Heisler L.K.; Lam D.D.; An appetite for life: brain regulation of hunger and satiety. Curr Opin Pharmacol 2017,37,100-106","journal-title":"Curr Opin Pharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.physbeh.2014.04.025","volume":"136","author":"Burger K.S.","year":"2014","unstructured":"Burger K.S.; Berner L.A.; A functional neuroimaging review of obesity, appetitive hormones and ingestive behavior. Physiol Behav 2014,136,121-127","journal-title":"Physiol Behav"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.tins.2012.12.001","volume":"36","author":"Adan R.A.","year":"2013","unstructured":"Adan R.A.; Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013,36(2),133-140","journal-title":"Trends Neurosci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S0006-3223(98)00186-3","volume":"44","author":"Leibowitz S.F.","year":"1998","unstructured":"Leibowitz S.F.; Alexander J.T.; Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry 1998,44(9),851-864","journal-title":"Biol Psychiatry"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.physbeh.2009.02.044","volume":"97","author":"Berridge K.C.","year":"2009","unstructured":"Berridge K.C.; \u2018Liking\u2019 and \u2018wanting\u2019 food rewards: brain substrates and roles in eating disorders. Physiol Behav 2009,97(5),537-550","journal-title":"Physiol Behav"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"62","DOI":"10.5582\/ddt.2016.01014","volume":"10","author":"Chen Y.","year":"2016","unstructured":"Chen Y.; Regulation of food intake and the development of anti-obesity drugs. Drug Discov Ther 2016,10(2),62-73","journal-title":"Drug Discov Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"Aronne L.J.","year":"2013","unstructured":"Aronne L.J.; Wadden T.A.; Peterson C.; Winslow D.; Odeh S.; Gadde K.M.; Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obesity (Silver Spring) 2013,21(11),2163-2171","journal-title":"Obesity (Silver Spring)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1136\/bmj.1.5588.352","volume":"1","author":"Munro J.F.","year":"1968","unstructured":"Munro J.F.; MacCuish A.C.; Wilson E.M.; Duncan L.J.; Comparison of continuous and intermittent anorectic therapy in obesity. BMJ 1968,1(5588),352-354","journal-title":"BMJ"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","volume":"95","author":"Verrotti A.","year":"2011","unstructured":"Verrotti A.; Scaparrotta A.; Agostinelli S.; Di Pillo S.; Chiarelli F.; Grosso S.; Topiramate-induced weight loss: a review. Epilepsy Res 2011,95(3),189-199","journal-title":"Epilepsy Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"507","DOI":"10.14310\/horm.2002.1438","volume":"12","author":"Kiortsis D.N.","year":"2013","unstructured":"Kiortsis D.N.; A review of the metabolic effects of controlled-release Phentermine\/Topiramate. Hormones (Athens) 2013,12(4),507-516","journal-title":"Hormones (Athens)"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1345\/aph.1R779","volume":"47","author":"Fleming J.W.","year":"2013","unstructured":"Fleming J.W.; McClendon K.S.; Riche D.M.; New obesity agents: lorcaserin and phentermine\/topiramate. Ann Pharmacother 2013,47(7-8),1007-1016","journal-title":"Ann Pharmacother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3810\/pgm.2013.11.2713","volume":"125","author":"Hess R.","year":"2013","unstructured":"Hess R.; Cross L.B.; The safety and efficacy of lorcaserin in the management of obesity. Postgrad Med 2013,125(6),62-72","journal-title":"Postgrad Med"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","volume":"376","author":"Greenway F.L.","year":"2010","unstructured":"Greenway F.L.; Fujioka K.; Plodkowski R.A.; Mudaliar S.; Guttadauria M.; Erickson J.; Kim D.D.; Dunayevich E.; Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010,376(9741),595-605","journal-title":"Lancet"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/oby.20309","volume":"21","author":"Apovian C.M.","year":"2013","unstructured":"Apovian C.M.; Aronne L.; Rubino D.; Still C.; Wyatt H.; Burns C.; Kim D.; Dunayevich E.; A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring) 2013,21(5),935-943","journal-title":"Obesity (Silver Spring)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/oby.2010.147","volume":"19","author":"Wadden T.A.","year":"2011","unstructured":"Wadden T.A.; Foreyt J.P.; Foster G.D.; Hill J.O.; Klein S.; O\u2019Neil P.M.; Perri M.G.; Pi-Sunyer F.X.; Rock C.L.; Erickson J.S.; Maier H.N.; Kim D.D.; Dunayevich E.; Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring) 2011,19(1),110-120","journal-title":"Obesity (Silver Spring)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.2337\/dc13-0234","volume":"36","author":"Hollander P.","year":"2013","unstructured":"Hollander P.; Gupta A.K.; Plodkowski R.; Greenway F.; Bays H.; Burns C.; Klassen P.; Fujioka K.; Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013,36(12),4022-4029","journal-title":"Diabetes Care"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/oby.21726","volume":"25","author":"Halseth A.","year":"2017","unstructured":"Halseth A.; Shan K.; Walsh B.; Gilder K.; Fujioka K.; Method-of-use study of naltrexone sustained release (SR)\/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring) 2017,25(2),338-345","journal-title":"Obesity (Silver Spring)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","volume":"132","author":"Baggio L.L.","year":"2007","unstructured":"Baggio L.L.; Drucker D.J.; Biology of incretins: GLP-1 and GIP. Gastroenterology 2007,132(6),2131-2157","journal-title":"Gastroenterology"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/BF03347560","volume":"28","author":"Rotella C.M.","year":"2005","unstructured":"Rotella C.M.; Pala L.; Mannucci E.; Glucagon-like peptide 1 (GLP-1) and metabolic diseases. J Endocrinol Invest 2005,28(8),746-758","journal-title":"J Endocrinol Invest"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2003.08.111","volume":"310","author":"Pala L.","year":"2003","unstructured":"Pala L.; Mannucci E.; Pezzatini A.; Ciani S.; Sardi J.; Raimondi L.; Ognibene A.; Cappadona A.; Vannelli B.G.; Rotella C.M.; Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochem Biophys Res Commun 2003,310(1),28-31","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/2040622313506730","volume":"5","author":"Troke R.C.","year":"2014","unstructured":"Troke R.C.; Tan T.M.; Bloom S.R.; The future role of gut hormones in the treatment of obesity. Ther Adv Chronic Dis 2014,5(1),4-14","journal-title":"Ther Adv Chronic Dis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.2337\/db11-0936","volume":"61","author":"Nyborg N.C.","year":"2012","unstructured":"Nyborg N.C.; M\u00f8lck A.M.; Madsen L.W.; Knudsen L.B.; The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012,61(5),1243-1249","journal-title":"Diabetes"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1021\/jm9909645","volume":"43","author":"Knudsen L.B.","year":"2000","unstructured":"Knudsen L.B.; Nielsen P.F.; Huusfeldt P.O.; Johansen N.L.; Madsen K.; Pedersen F.Z.; Th\u00f8gersen H.; Wilken M.; Agers\u00f8 H.; Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000,43(9),1664-1669","journal-title":"J Med Chem"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s13300-016-0180-0","volume":"7","author":"Ostawal A.","year":"2016","unstructured":"Ostawal A.; Mocevic E.; Kragh N.; Xu W.; Clinical effectiveness of liraglutide in type 2 diabetes treatment in the real-world setting: a systematic literature review. Diabetes Ther 2016,7(3),411-438","journal-title":"Diabetes Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","volume":"374","author":"Astrup A.","year":"2009","unstructured":"Astrup A.; R\u00f6ssner S.; Van Gaal L.; Rissanen A.; Niskanen L.; Al Hakim M.; Madsen J.; Rasmussen M.F.; Lean M.E.; Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009,374(9701),1606-1616","journal-title":"Lancet"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1016\/0016-5085(94)90559-2","volume":"107","author":"Lowe M.E.","year":"1994","unstructured":"Lowe M.E.; Pancreatic triglyceride lipase and colipase: insights into dietary fat digestion. Gastroenterology 1994,107(5),1524-1536","journal-title":"Gastroenterology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"E1183","DOI":"10.1152\/ajpendo.90899.2008","volume":"296","author":"Iqbal J.","year":"2009","unstructured":"Iqbal J.; Hussain M.M.; Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009,296(6),E1183-E1194","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1016\/S0021-9258(18)93813-5","volume":"239","author":"Mattson F.H.","year":"1964","unstructured":"Mattson F.H.; Volpenhein R.A.; THE DIGESTION AND ABSORPTION OF TRIGLYCERIDES. J Biol Chem 1964,239,2772-2777","journal-title":"J Biol Chem"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0163-7827(03)00050-X","volume":"43","author":"Mu H.","year":"2004","unstructured":"Mu H.; H\u00f8y C.E.; The digestion of dietary triacylglycerols. Prog Lipid Res 2004,43(2),105-133","journal-title":"Prog Lipid Res"},{"key":"ref=37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010380","volume":"5","author":"Masson C.J.","year":"2010","unstructured":"Masson C.J.; Plat J.; Mensink R.P.; Namiot A.; Kisielewski W.; Namiot Z.; F\u00fcllekrug J.; Ehehalt R.; Glatz J.F.; Pelsers M.M.; Fatty acid- and cholesterol transporter protein expression along the human intestinal tract. PLoS One 2010,5(4)","journal-title":"PLoS One"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11745-003-1089-6","volume":"38","author":"Luiken J.J.","year":"2003","unstructured":"Luiken J.J.; Koonen D.P.; Coumans W.A.; Pelsers M.M.; Binas B.; Bonen A.; Glatz J.F.; Long-chain fatty acid uptake by skeletal muscle is impaired in homozygous, but not heterozygous, heart-type-FABP null mice. Lipids 2003,38(4),491-496","journal-title":"Lipids"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0005-2760(88)90260-3","volume":"962","author":"Borgstrom B.","year":"1988","unstructured":"Borgstrom B.; Mode of action of tetrahydrolipstatin: a derivative of the naturally occurring lipase inhibitor lipstatin. Biochim Biophys Acta 1988,962(3),308-316","journal-title":"Biochim Biophys Acta"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.7164\/antibiotics.40.1081","volume":"40","author":"Weibel E.K.","year":"1987","unstructured":"Weibel E.K.; Hadvary P.; Hochuli E.; Kupfer E.; Lengsfeld H.; Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot (Tokyo) 1987,40(8),1081-1085","journal-title":"J Antibiot (Tokyo)"},{"key":"ref=41","first-page":"35","volume":"11","author":"Hogan S.","year":"1987","unstructured":"Hogan S.; Fleury A.; Hadvary P.; Lengsfeld H.; Meier M.K.; Triscari J.; Sullivan A.C.; Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase. Int J Obes 1987,11(Suppl. 3),35-42","journal-title":"Int J Obes"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/hlca.19870700124","volume":"70","author":"Barbier P.","year":"1987","unstructured":"Barbier P.; Schneider F.; Syntheses of Tetrahydrolipstatin and Absolute Configuration of Tetrahydrolipstatin and Lipstatin. Helv Chim Acta 1987,70(1),196-202","journal-title":"Helv Chim Acta"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/j.1552-4604.1995.tb04034.x","volume":"35","author":"Zhi J.","year":"1995","unstructured":"Zhi J.; Melia A.T.; Eggers H.; Joly R.; Patel I.H.; Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995,35(11),1103-1108","journal-title":"J Clin Pharmacol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/clpt.1994.104","volume":"56","author":"Zhi J.","year":"1994","unstructured":"Zhi J.; Melia A.T.; Guerciolini R.; Chung J.; Kinberg J.; Hauptman J.B.; Patel I.H.; Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994,56(1),82-85","journal-title":"Clin Pharmacol Ther"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","volume":"352","author":"Sj\u00f6str\u00f6m L.","year":"1998","unstructured":"Sj\u00f6str\u00f6m L.; Rissanen A.; Andersen T.; Boldrin M.; Golay A.; Koppeschaar H.P.; Krempf M.; Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998,352(9123),167-172","journal-title":"Lancet"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1517\/14656566.3.5.599","volume":"3","author":"Kelley D.E.","year":"2002","unstructured":"Kelley D.E.; Jneidi M.; Orlistat in the treatment of Type 2 diabetes mellitus. Expert Opin Pharmacother 2002,3(5),599-605","journal-title":"Expert Opin Pharmacother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","volume":"25","author":"Miles J.M.","year":"2002","unstructured":"Miles J.M.; Leiter L.; Hollander P.; Wadden T.; Anderson J.W.; Doyle M.; Foreyt J.; Aronne L.; Klein S.; Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002,25(7),1123-1128","journal-title":"Diabetes Care"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0802475","volume":"27","author":"Padwal R.","year":"2003","unstructured":"Padwal R.; Li S.K.; Lau D.C.; Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003,27(12),1437-1446","journal-title":"Int J Obes Relat Metab Disord"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.phrs.2017.05.022","volume":"122","author":"Sahebkar A.","year":"2017","unstructured":"Sahebkar A.; Simental-Mend\u00eda L.E.; Reiner \u017d.; Kovanen P.T.; Simental-Mend\u00eda M.; Bianconi V.; Pirro M.; Effect of orlistat on plasma lipids and body weight: A systematic review and meta-analysis of 33 randomized controlled trials. Pharmacol Res 2017,122,53-65","journal-title":"Pharmacol Res"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1309-1319, e7","DOI":"10.1053\/j.gastro.2017.12.024","volume":"154","author":"Khera R.","year":"2018","unstructured":"Khera R.; Pandey A.; Chandar A.K.; Murad M.H.; Prokop L.J.; Neeland I.J.; Berry J.D.; Camilleri M.; Singh S.; Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology 2018,154(5),1309-1319, e7","journal-title":"Gastroenterology"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.numecd.2007.03.010","volume":"18","author":"Mannucci E.","year":"2008","unstructured":"Mannucci E.; Dicembrini I.; Rotella F.; Rotella C.M.; Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 2008,18(5),342-348","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/09513590.2017.1407752","volume":"34","author":"Song J.","year":"2018","unstructured":"Song J.; Ruan X.; Gu M.; Wang L.; Wang H.; Mueck A.O.; Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecol Endocrinol 2018,34(5),413-417","journal-title":"Gynecol Endocrinol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1001\/jama.2014.732","volume":"311","author":"Ogden C.L.","year":"2014","unstructured":"Ogden C.L.; Carroll M.D.; Kit B.K.; Flegal K.M.; Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014,311(8),806-814","journal-title":"JAMA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1186\/1471-2458-14-806","volume":"14","author":"Wijnhoven T.M.","year":"2014","unstructured":"Wijnhoven T.M.; van Raaij J.M.; Spinelli A.; Starc G.; Hassapidou M.; Spiroski I.; Rutter H.; Martos \u00c9.; Rito A.I.; Hovengen R.; P\u00e9rez-Farin\u00f3s N.; Petrauskiene A.; Eldin N.; Braeckevelt L.; Pudule I.; Kune\u0161ov\u00e1 M.; Breda J.; WHO European Childhood Obesity Surveillance Initiative: body mass index and level of overweight among 6-9-year-old children from school year 2007\/2008 to school year 2009\/2010. BMC Public Health 2014,14,806","journal-title":"BMC Public Health"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1475-2891-13-69","volume":"13","author":"Lazzeri G.","year":"2014","unstructured":"Lazzeri G.; Giacchi M.V.; Spinelli A.; Pammolli A.; Dalmasso P.; Nardone P.; Lamberti A.; Cavallo F.; Overweight among students aged 11-15 years and its relationship with breakfast, area of residence and parents\u2019 education: results from the Italian HBSC 2010 cross-sectional study. Nutr J 2014,13,69","journal-title":"Nutr J"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1210\/jc.2016-2574","volume":"102","author":"Rajjo T.","year":"2017","unstructured":"Rajjo T.; Mohammed K.; Alsawas M.; Ahmed A.T.; Farah W.; Asi N.; Almasri J.; Prokop L.J.; Murad M.H.; Treatment of pediatric obesity: an umbrella systematic review. J Clin Endocrinol Metab 2017,102(3),763-775","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","volume":"29","author":"Gupta A.K.","year":"2011","unstructured":"Gupta A.K.; Nasothimiou E.G.; Chang C.L.; Sever P.S.; Dahl\u00f6f B.; Poulter N.R.; Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens 2011,29(10),2004-2013","journal-title":"J Hypertens"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.1365-2710.2011.01280.x","volume":"37","author":"Derosa G.","year":"2012","unstructured":"Derosa G.; Cicero A.F.; D\u2019Angelo A.; Fogari E.; Maffioli P.; Effects of 1-year orlistat treatment compared to placebo on insulin resistance parameters in patients with type 2 diabetes. J Clin Pharm Ther 2012,37(2),187-195","journal-title":"J Clin Pharm Ther"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/obr.12318","volume":"16","author":"Aldekhail N.M.","year":"2015","unstructured":"Aldekhail N.M.; Logue J.; McLoone P.; Morrison D.S.; Effect of orlistat on glycaemic control in overweight and obese patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2015,16(12),1071-1080","journal-title":"Obes Rev"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1463-1326.2008.00970.x","volume":"11","author":"Jacob S.","year":"2009","unstructured":"Jacob S.; Rabbia M.; Meier M.K.; Hauptman J.; Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009,11(4),361-371","journal-title":"Diabetes Obes Metab"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1177\/2042098613489721","volume":"4","author":"Cheung B.M.","year":"2013","unstructured":"Cheung B.M.; Cheung T.T.; Samaranayake N.R.; Safety of antiobesity drugs. Ther Adv Drug Saf 2013,4(4),171-181","journal-title":"Ther Adv Drug Saf"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"pii: bcr-2016-218623","DOI":"10.1136\/bcr-2016-218623","volume":"2017","author":"Solomon L.R.","year":"2017","unstructured":"Solomon L.R.; Nixon A.C.; Ogden L.; Nair B.; Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease. BMJ Case Rep 2017,2017,pii: bcr-2016-218623","journal-title":"BMJ Case Rep"},{"key":"ref=63","doi-asserted-by":"publisher","DOI":"10.5812\/ijem.19678","volume":"13","author":"Esteghamati A.","year":"2015","unstructured":"Esteghamati A.; Mazaheri T.; Vahidi Rad M.; Noshad S.; Complementary and alternative medicine for the treatment of obesity: a critical review. Int J Endocrinol Metab 2015,13(2)","journal-title":"Int J Endocrinol Metab"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1007\/s00592-010-0190-8","volume":"49","author":"Blank S.E.","year":"2012","unstructured":"Blank S.E.; Johnson E.C.; Weeks D.K.; Wysham C.H.; Circulating dendritic cell number and intracellular TNF-\u03b1 production in women with type 2 diabetes. Acta Diabetol 2012,49(Suppl. 1),S25-S32","journal-title":"Acta Diabetol"},{"key":"ref=65","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2012-000854","volume":"2","author":"Khan M.H.","year":"2012","unstructured":"Khan M.H.; Tanimoto T.; Nakanishi Y.; Yoshida N.; Tsuboi H.; Kimura K.; Public health concerns for anti-obesity medicines imported for personal use through the internet: a cross-sectional study. BMJ Open 2012,2(3)","journal-title":"BMJ Open"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1146\/annurev-pharmtox-010617-052844","volume":"58","author":"Ronis M.J.J.","year":"2018","unstructured":"Ronis M.J.J.; Pedersen K.B.; Watt J.; Adverse effects of nutraceuticals and dietary supplements. Annu Rev Pharmacol Toxicol 2018,58,583-601","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=67","first-page":"370","volume":"245","author":"Fan Y.","year":"2017","unstructured":"Fan Y.; Adam T.J.; McEwan R.; Pakhomov S.V.; Melton G.B.; Zhang R.; Detecting signals of interactions between warfarin and dietary supplements in electronic health records. Stud Health Technol Inform 2017,245,370-374","journal-title":"Stud Health Technol Inform"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1016\/j.jada.2006.09.014","volume":"106","author":"Sharpe P.A.","year":"2006","unstructured":"Sharpe P.A.; Granner M.L.; Conway J.M.; Ainsworth B.E.; Dobre M.; Availability of weight-loss supplements: Results of an audit of retail outlets in a southeastern city. J Am Diet Assoc 2006,106(12),2045-2051","journal-title":"J Am Diet Assoc"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2165\/00002018-200932060-00002","volume":"32","author":"Chan T.Y.","year":"2009","unstructured":"Chan T.Y.; Potential risks associated with the use of herbal anti-obesity products. Drug Saf 2009,32(6),453-456","journal-title":"Drug Saf"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/15563650.2017.1398328","volume":"56","author":"Cohen P.A.","year":"2018","unstructured":"Cohen P.A.; Travis J.C.; Keizers P.H.J.; Deuster P.; Venhuis B.J.; Four experimental stimulants found in sports and weight loss supplements: 2-amino-6-methylheptane (octodrine), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylamylamine (1,3-DMAA) and 1,3-dimethylbutylamine (1,3-DMBA). Clin Toxicol (Phila) 2018,56(6),421-426","journal-title":"Clin Toxicol (Phila)"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.jchromb.2016.10.019","volume":"1038","author":"Dos Santos V.B.","year":"2016","unstructured":"Dos Santos V.B.; Daniel D.; Singh M.; do Lago C.L.; Amphetamine and derivatives in natural weight loss pills and dietary supplements by capillary electrophoresis-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2016,1038,19-25","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12906-015-0955-2","volume":"15","author":"Yoshida N.","year":"2015","unstructured":"Yoshida N.; Numano M.; Nagasaka Y.; Ueda K.; Tsuboi H.; Tanimoto T.; Kimura K.; Study on health hazards through medicines purchased on the Internet: a cross-sectional investigation of the quality of anti-obesity medicines containing crude drugs as active ingredients. BMC Complement Altern Med 2015,15(1),430","journal-title":"BMC Complement Altern Med"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.3748\/wjg.15.3073","volume":"15","author":"Hasani-Ranjbar S.","year":"2009","unstructured":"Hasani-Ranjbar S.; Nayebi N.; Larijani B.; Abdollahi M.; A systematic review of the efficacy and safety of herbal medicines used in the treatment of obesity. World J Gastroenterol 2009,15(25),3073-3085","journal-title":"World J Gastroenterol"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00103-016-2506-5","volume":"60","author":"Bakhyia N.","year":"2017","unstructured":"Bakhyia N.; Dusemund B.; Richter K.; Lindtner O.; Hirsch-Ernst K.I.; Sch\u00e4fer B.; Lampen A.; [Risk assessment of synephrine in dietary supplements] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2017,60(3),323-331","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/BF03160960","volume":"4","author":"Haller C.","year":"2008","unstructured":"Haller C.; Kearney T.; Bent S.; Ko R.; Benowitz N.; Olson K.; Dietary supplement adverse events: report of a one-year poison center surveillance project. J Med Toxicol 2008,4(2),84-92","journal-title":"J Med Toxicol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1210\/en.2014-1933","volume":"156","author":"Hernandez A.","year":"2015","unstructured":"Hernandez A.; 3,5-diiodo-L-thyronine (t2) in dietary supplements: what are the physiological effects? Endocrinology 2015,156(1),5-7","journal-title":"Endocrinology"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1089\/thy.2013.0101","volume":"23","author":"Kang G.Y.","year":"2013","unstructured":"Kang G.Y.; Parks J.R.; Fileta B.; Chang A.; Abdel-Rahim M.M.; Burch H.B.; Bernet V.J.; Thyroxine and triiodothyronine content in commercially available thyroid health supplements. Thyroid 2013,23(10),1233-1237","journal-title":"Thyroid"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/0140-6736(92)91305-R","volume":"339","author":"Pye K.G.","year":"1992","unstructured":"Pye K.G.; Kelsey S.M.; House I.M.; Newland A.C.; Severe dyserythropoiesis and autoimmune thrombocytopenia associated with ingestion of kelp supplements. Lancet 1992,339(8808),1540","journal-title":"Lancet"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3122\/jabfm.11.6.478","volume":"11","author":"Eliason B.C.","year":"1998","unstructured":"Eliason B.C.; Transient hyperthyroidism in a patient taking dietary supplements containing kelp. J Am Board Fam Pract 1998,11(6),478-480","journal-title":"J Am Board Fam Pract"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.beem.2009.08.010","volume":"24","author":"B\u00fcrgi H.","year":"2010","unstructured":"B\u00fcrgi H.; Iodine excess. Best Pract Res Clin Endocrinol Metab 2010,24(1),107-115","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ctim.2013.05.007","volume":"21","author":"Astell K.J.","year":"2013","unstructured":"Astell K.J.; Mathai M.L.; Su X.Q.; Plant extracts with appetite suppressing properties for body weight control: a systematic review of double blind randomized controlled clinical trials. Complement Ther Med 2013,21(4),407-416","journal-title":"Complement Ther Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.mcna.2017.08.010","volume":"102","author":"Saunders K.H.","year":"2018","unstructured":"Saunders K.H.; Umashanker D.; Igel L.I.; Kumar R.B.; Aronne L.; J. Obesity pharmacotherapy. Med Clin North Am 2018,102(1),135-148","journal-title":"Med Clin North Am"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169317","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T19:21:47Z","timestamp":1662837707000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169317\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":82,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2,18]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867326666190124121725","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-02-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}